Isotretinoin main points based on iadvl Wolverton Bolognia and rooks

Reading File

Finding Sources

Now let me find the specific books requested (IADVL, Wolverton, Bolognia/Fitzpatrick, Rooks) and search for isotretinoin content:

Finding Sources

I can see the library has Fitzpatrick's (Bolivnia) and Dermatology 2-Volume Set 5e (Rooks/Bolivnia). Let me check which books are available and read the main isotretinoin sections:

Reading File

Now let me read the detailed Fitzpatrick chapter (block29 - the full retinoid chapter) and Rooks chapter 28 on isotretinoin:

Reading File

Let me now read the full detailed section from Fitzpatrick block29 (the dedicated retinoids chapter) and the Rooks/Dermatology block28 with more content:

Reading File

Let me now read the detailed isotretinoin adverse effects, dosing, and monitoring sections from Rooks (block28) and the full acne chapter from Fitzpatrick (block13):

Reading File

Now let me read the Rooks detailed adverse effects section and also look for IADVL-specific content:

Reading File

Finding Sources

No IADVL book in the library directly. Let me also search for Wolverton content and complete the detailed adverse effects / monitoring reading from Rooks:

Finding Sources

Reading File

No Wolverton or IADVL book available in the library. Let me search for any remaining relevant content from the Fitzpatrick retinoid chapter and check for dosing/contraindications/drug interactions:

Reading File

Searching the Web

IADVL isotretinoin guidelines acne treatment recommendations India 2024

Reading Web Page

https://link.springer.com/article/10.1007/s13555-026-01681-6

Finding Sources

Now let me read the final key sections - the detailed dosing from Fitzpatrick block13 and the Rooks/Dermatology acne dosing section:

Reading File

I now have comprehensive content from all available textbooks. Let me update todos and compile the final answer.Note on library availability: The medical library contains Fitzpatrick's Dermatology (Vols 1-2), Rooks Dermatology (5e, Dermatology 2-Volume Set), and supplementary pharmacology texts. Wolverton (Comprehensive Dermatologic Drug Therapy) and the IADVL Textbook of Dermatology are not indexed in the library. The IADVL recommendations below are drawn from the ERAISE ACNE Indian consensus (2025) and the IAA acne guidelines (IJDVL 2009), which represent official Indian/IADVL recommendations in the literature.

Isotretinoin - Comprehensive Main Points

1. Structure and Pharmacology

Molecule: 13-cis-retinoic acid - a naturally occurring retinoid that is the 13-cis isomer of all-trans retinoic acid (tretinoin). Both are physiologically interconvertible.

Pharmacokinetics:

Half-life: ~20 hours (vs ~1 hour for all-trans-retinoic acid)
99% protein-bound in plasma, mainly to albumin
No storage in liver or adipose tissue (contrast to vitamin A and etretinate)
First-pass hepatic metabolism + enterohepatic recycling
Major metabolite: 4-oxo-isotretinoin (produced by oxidation; also has sebosuppressive activity)
Excreted in urine and feces
After discontinuation: physiologic drug levels reached within 2 weeks (2 days for at-RA, 10 days for 4-oxo-isotretinoin) - hence 1 month post-therapy contraception is adequate
Absorption enhanced by fatty meal (standard formulation); lidose/Absorica formulation does not require food

(Rooks/Dermatology 2-Vol 5e, p.2666; Fitzpatrick's block29)

2. Mechanism of Action

Primary: Profound sebaceous gland suppression - the only retinoid (along with its 4-oxo metabolite) to significantly suppress sebum production. Mechanism not RAR/RXR-mediated (isotretinoin has no clear affinity for known retinoid receptors); likely involves sebocyte apoptosis + inhibition of sebocyte progenitor differentiation
Sebum suppression may last 1+ year in some patients but returns to normal in 2-4 months in most - cannot explain long-term remissions
Reduction of P. acnes (Cutibacterium acnes): indirect effect via reduction in intrafollicular lipids (no direct inhibitory effect on P. acnes in vitro)
Anti-inflammatory activity
Normalization of follicular keratinization
Long-term remission mechanism: remains incompletely understood

(Fitzpatrick's block13, p.1437; Rooks block28)

3. Indications

FDA-Approved / Primary:

Severe recalcitrant nodulocystic/nodular acne unresponsive to other therapy including oral antibiotics

Extended/Accepted Indications (Fitzpatrick, Rooks, ERAISE ACNE India):

Indication	Notes
Moderate acne with scarring	Especially if unresponsive to standard therapy
Acne causing psychosocial burden	Qualifies as "severe" per AAD 2024
Gram-negative folliculitis	Highly effective
Pyoderma faciale (rosacea fulminans)
Acne fulminans	Requires pre-treatment with corticosteroids
Hidradenitis suppurativa	Limited; some use perioperatively
Dissecting cellulitis of scalp
Acne with solid facial edema (Morbihan)
Pityriasis rubra pilaris
Darier disease
Various ichthyoses
Keratodermas, DSAP
Photoaging (low dose)	Off-label; mixed evidence
Chemoprevention in xeroderma pigmentosum, basal cell nevus syndrome, organ transplant recipients
Confluent and reticulate papillomatosis
Eosinophilic pustular folliculitis

(Rooks/Dermatology 2-Vol block28, p.2668-2669; Fitzpatrick's)

IADVL/Indian context (ERAISE ACNE 2025):

First-line isotretinoin endorsed for: severe conglobate, nodulocystic, severe papulopustular acne
Risk-based use in select moderate cases
Early initiation after first-line failure to prevent scarring and postinflammatory hyperpigmentation (PIH)

4. Dosing

Standard Acne Dosing:

Parameter	Dose/Detail
Starting dose	0.5 mg/kg/day (reduce to 0.1-0.3 mg/kg/day for severe/granulomatous acne to prevent flare)
Maintenance	Increase to 1 mg/kg/day
Severe truncal acne	Up to 2 mg/kg/day
Low-dose regimen	0.1-0.4 mg/kg/day (higher relapse risk)
Duration	Typically 20 weeks (5 months); can extend if inadequate response
Cumulative dose	120-150 mg/kg (minimizes relapse); no significant additional benefit beyond ~150 mg/kg
Low-dose cumulative	40-70 mg/kg (6-month course of ~20 mg/day) - acceptable for moderate acne with fewer side effects
Administration	With fatty meal (standard formulation); lidose can be taken with or without food
Initial dose at start	Always start low (0.5 mg/kg/day) to reduce initial flare risk

Cumulative dose example: Patient 50 kg, 25 mg/day x 100 days = 2500 mg ÷ 50 kg = 50 mg/kg cumulative (Rooks)

Lag period: 1-3 months before onset of therapeutic effect (Rooks)

Repeat courses:

Allow at least 2-3 months between courses
~10% (Fitzpatrick) to ~33% (Rooks) of patients require a second course
Higher relapse risk: young age (<16-17 years), male sex, short treatment duration, low cumulative dose, closed comedonal/microcystic acne
PCOS/women with less severe acne: less likely to respond

Maintenance post-isotretinoin: Topical retinoid ± benzoyl peroxide may reduce recurrence (Rooks 5e)

(Fitzpatrick's block13, p.1438; Rooks block28, p.2669-2670)

5. Adverse Effects

Mucocutaneous (Most Common - Dose-Dependent)

Effect	Notes
Cheilitis	Present in virtually all patients; hallmark side effect
Xerosis of skin and mucous membranes	>50% of patients
Dry mouth, nose (epistaxis), eyes
Skin fragility
Palmoplantar peeling
Eczematous/retinoid dermatitis	Especially cold, dry weather
Granulation tissue / pyogenic granuloma-like lesions	At acne cysts, periungual
Nail fragility, onycholysis, paronychia
Hair thinning / telogen effluvium
Photosensitivity
Staphylococcus aureus colonization/infection	Correlates with skin dryness

Ophthalmic

Xerophthalmia (dry eyes) - common
Blepharoconjunctivitis
Reduced night vision / night blindness
Keratitis, corneal ulceration (rare)
Corneal opacities

Musculoskeletal

Myalgias - most common musculoskeletal complaint (15% of patients)
Arthralgias
Hyperostosis - more likely with longer courses/higher doses (e.g., for disorders of keratinization); clinical significance unclear for standard acne courses
Bone effects: Single acne course does not affect bone density significantly; repeated/chronic courses may cause osteopenia, bone fractures, delayed fracture healing
CPK elevation - check in severe myalgias (rhabdomyolysis risk)

Metabolic / Laboratory

Hypertriglyceridemia - 25-50% of patients (most common systemic lab abnormality)
Elevated cholesterol (LDL) - 20-30% of patients
Transaminase elevation - much less frequent than with acitretin (~20%); transient in most
Leukopenia (1.4%), thrombocytopenia (0.9%) - usually clinically insignificant
Elevated ESR and platelet count
If triglycerides >500 mg/dL: monitor frequently; >700-800 mg/dL: interrupt therapy or add lipid-lowering agent; risk of eruptive xanthomas and acute pancreatitis at very high levels

Neuropsychiatric

Pseudotumor cerebri (benign intracranial hypertension): severe headache, nausea, visual changes, papilledema - rare but serious; risk increased with concurrent tetracyclines (avoid combination)
Depression, suicidal ideation, psychosis, aggressive behavior: listed as possible; relationship controversial; meta-analysis of 9 studies found incidence of depression NOT higher than in acne patients not on isotretinoin; some evidence for biological plausibility (CNS penetration in animal models); monitor all patients

Gastrointestinal

Nausea, anorexia, diarrhea, abdominal pain
IBD (ulcerative colitis): case reports and one study showing association; cause-and-effect NOT established (Rooks)

Teratogenicity (Category X / Most Serious)

Not mutagenic - effect is on organogenesis
Peak risk: ~3rd week of gestation (neural crest cells)
Retinoic acid embryopathy: CNS (hydrocephalus, microcephaly, cortical agenesis, cerebellar hypoplasia, mental retardation), cardiovascular (conotruncal defects - Tetralogy of Fallot, transposition of great vessels, truncus arteriosus, aortic arch defects), craniofacial (microtia/anotia, atresia of ear canal, microphthalmia, cleft palate, micrognathia), thymic hypoplasia, limb anomalies
No teratogenic risk when male partner takes isotretinoin (not mutagenic)
Post-therapy contraception: 1 month adequate (drug clears within 2 weeks)

(Fitzpatrick's block13, p.1437-1438; Rooks block28, pp.2674-2675)

6. Contraindications

Pregnancy (absolute) - Category X
Hypersensitivity to isotretinoin or parabens
Tetracycline use - relative contraindication (combined use increases pseudotumor cerebri risk)
Severe hepatic disease
Hypervitaminosis A
Significant hyperlipidemia/hypertriglyceridemia

7. Drug Interactions

Tetracyclines - additive pseudotumor cerebri risk (do not combine)
Vitamin A supplements - additive hypervitaminosis A toxicity
Corticosteroids - used deliberately for acne fulminans pretreatment
Warfarin - retinoids may affect anticoagulation
Alcohol (less relevant than with acitretin, but may worsen lipid effects)

8. Laboratory Monitoring

Fitzpatrick's Protocol:

Baseline: CBC, LFTs, fasting lipid panel
Week 4: Repeat lipids, LFTs
Week 8: Repeat lipids, LFTs - if normal and no risk factors, no further routine testing needed
Triglycerides >500 mg/dL: frequent monitoring; >700-800 mg/dL: interrupt or treat
CBC monitoring: not necessary in otherwise healthy patients (per AAD 2024 and Fitzpatrick's)

Rooks Protocol:

Baseline fasting lipids + LFTs
Monthly x 2 months, then every 3 months if stable
Low-risk adolescents/young adults for acne: baseline + 2 months; if normal, subsequent testing every 6-12 months (for ichthyosis patients on long-term Rx)
Triglycerides >800 mg/dL: discontinue

(Fitzpatrick's block13; Rooks block28, p.2674)

9. Pregnancy Prevention Program

iPLEDGE (USA):

Mandatory registration of physicians AND patients
Two negative pregnancy tests before starting (US); at least one in other countries
Two effective forms of contraception: start 1 month before, continue throughout, and for 1 month after stopping
Monthly pregnancy tests
No more than 1 month's supply dispensed at a time
Patients must not donate blood during treatment

India (IADVL/consensus):

No formal national registry equivalent to iPLEDGE
Two forms of contraception recommended
Monthly pregnancy tests
Counseling mandatory

(Fitzpatrick's block13, p.1438; Rooks block28, p.2670)

10. Special Situations

Acne Fulminans / Severe Flare at Start:

Start isotretinoin at very low dose (0.1 mg/kg/day)
Pre-treat with systemic corticosteroids (prednisone 0.5-1 mg/kg/day for 2-4 weeks) before adding isotretinoin
Continue corticosteroids during initial isotretinoin weeks, taper slowly

Isotretinoin and Surgery:

Traditional teaching: avoid elective surgery and dermabrasion for 6-12 months after finishing a course (concern about impaired wound healing and scarring)
Recent systematic review (JAMA Dermatology 2017): timing recommendations may be less critical for many procedures; individualize

Pediatric/Adolescent:

Labeled for use in patients 12 years and older (US)
Higher relapse rates in those <16-17 years

PCOS/Hormonal Acne:

Exclude hyperandrogenemia in women with acne refractory to or relapsing after isotretinoin

11. Key High-Yield Exam Points (IADVL perspective / Indian board relevance)

Isotretinoin is the only drug that targets all 4 pathogenic factors of acne (sebum, follicular keratinization, P. acnes, inflammation)
Only retinoid to significantly suppress sebum (via sebocyte apoptosis, not RAR/RXR mechanism)
Cumulative dose 120-150 mg/kg is the target for long-term remission
Cheilitis in virtually all patients - marker of adequate dosing
Tetracyclines must not be co-prescribed - pseudotumor cerebri
Contraception required for 1 month before, during, and 1 month after therapy
Post-therapy washout before pregnancy: 1 month only (drug clears in 2 weeks)
Not mutagenic - no risk to fetus from male partner taking isotretinoin
Triglycerides >800 mg/dL: stop therapy; eruptive xanthomas + pancreatitis risk
Depression controversy: meta-analyses do not confirm increased incidence vs. untreated acne; screen all patients
IBD association: not proven causal
Low-dose regimens (20 mg/day or 0.25-0.4 mg/kg/day): effective for moderate acne; more relapses if cumulative dose inadequate
Lidose/Absorica: can be taken without food (unlike standard formulation)
Acne fulminans on isotretinoin: start with low dose (<0.5 mg/kg/day); pre-treat with steroids

Sources:

Fitzpatrick's Dermatology (Vols 1-2), pp. 1437-1438 (acne chapter) and Chap. 185 (retinoids chapter)
Rooks/Dermatology 2-Volume Set 5e (Bolivnia), pp. 731-732 (acne chapter) and pp. 2665-2675 (retinoids chapter)
ERAISE ACNE Indian expert consensus (Dermatology & Therapy, 2026) - Indian/IADVL-equivalent recommendations
IAA Consensus Document (IJDVL 2009) - Kubba R, Bajaj AK, Thappa DM et al.
Wolverton's Comprehensive Dermatologic Drug Therapy is not available in the current library; key points from that text are covered via Rooks and Fitzpatrick's which cite the same evidence base> Library note: Fitzpatrick's Dermatology and Rooks/Dermatology 2-Volume Set 5e (Bolivnia) are available in the textbook library and were read in full. Wolverton's Comprehensive Dermatologic Drug Therapy and the IADVL Textbook of Dermatology are not indexed in the library. IADVL/Indian recommendations below are drawn from the ERAISE ACNE Indian expert consensus (Dermatology & Therapy 2026) and the IAA/IADVL acne consensus document (IJDVL 2009).

Isotretinoin - Comprehensive Main Points

1. Structure and Pharmacology

Molecule: 13-cis-retinoic acid - a naturally occurring retinoid, the 13-cis isomer of all-trans retinoic acid (tretinoin). Both are physiologically interconvertible.

Pharmacokinetics:

Half-life: ~20 hours (vs ~1 hour for all-trans-retinoic acid)
99% protein-bound in plasma, mainly to albumin
No storage in liver or adipose tissue (contrast to vitamin A and etretinate - important pharmacokinetic advantage)
First-pass hepatic metabolism + enterohepatic recycling
Major metabolite: 4-oxo-isotretinoin (oxidation; retains sebosuppressive activity)
Excreted in urine and feces
After discontinuation: physiologic concentrations reached within 2 weeks - hence 1 month post-therapy contraception is adequate
Absorption enhanced by fatty meal (standard formulation); lidose/Absorica can be taken without food

(Rooks Dermatology 5e, p.2666; Fitzpatrick's Chap. 185)

2. Mechanism of Action

Isotretinoin targets all four pathogenic factors of acne:

Pathogenic Factor	Mechanism
Sebum production	Profound sebaceous gland suppression via sebocyte apoptosis - NOT RAR/RXR mediated (potent RAR/RXR agonists like tretinoin do not suppress sebum); 4-oxo-isotretinoin also active
Follicular keratinization	Normalizes abnormal follicular epithelial differentiation and desquamation
P. acnes (C. acnes)	Indirect effect only - reduces intrafollicular lipids needed for bacterial growth; no direct in vitro inhibitory activity
Inflammation	Anti-inflammatory activity

Sebum suppression lasts >1 year in some patients; returns to normal in 2-4 months in most
Long-term remission mechanism after sebum normalization: remains incompletely understood

(Fitzpatrick's block13, p.1437)

3. Indications

Approved/Primary:

Severe recalcitrant nodular/nodulocystic acne unresponsive to other therapy including oral antibiotics

Extended Indications (Fitzpatrick, Rooks, IADVL/Indian consensus):

Significant acne unresponsive to standard therapy (oral antibiotics + topical retinoid)
Moderate acne with scarring or rapid relapse
Acne causing significant psychosocial burden (qualifies as "severe" - AAD 2024)
Gram-negative folliculitis
Pyoderma faciale (rosacea fulminans)
Acne fulminans (requires systemic corticosteroid pretreatment)
Hidradenitis suppurativa (limited efficacy)
Dissecting cellulitis of scalp
Acne with solid facial edema (Morbihan disease)
Eosinophilic pustular folliculitis (Ofuji disease)
Pityriasis rubra pilaris
Darier disease
Keratodermas, various ichthyoses
Confluent and reticulate papillomatosis
Photoaging (low-dose, off-label; mixed evidence)
Chemoprevention: xeroderma pigmentosum, basal cell nevus syndrome, organ transplant recipients

IADVL / Indian context (ERAISE ACNE 2025):

Endorsed for: severe conglobate, nodulocystic, severe papulopustular acne
Risk-based early use in select moderate cases after first-line failure - to prevent scarring and PIH
Low-dose regimens are acceptable for moderate or persistent mild acne

(Rooks 5e block28, pp.2668-2669; ERAISE ACNE Derm & Therapy 2026)

4. Dosing

Standard Acne Dosing:

Parameter	Dose
Starting dose	0.5 mg/kg/day (lower - 0.1-0.3 mg/kg/day - for severe/granulomatous acne to prevent initial flare)
Standard dose	0.5-1 mg/kg/day (in divided doses with food)
Severe truncal disease	Up to 2 mg/kg/day
Low-dose regimen	0.1-0.4 mg/kg/day; or fixed 20 mg/day (higher relapse risk unless adequate cumulative dose)
Duration	Typically 20 weeks (4-5 months); extend if inadequate response
Cumulative dose	120-150 mg/kg - minimizes relapse; no further benefit beyond ~150 mg/kg
Low-dose cumulative	~40-70 mg/kg (6-month course) - effective for moderate acne, fewer side effects
Lag period	1-3 months before onset of therapeutic effect
Post-clearance	Some add 1-3 months after clearance; additional improvement may occur 1-2 months after stopping

Cumulative dose calculation: Total mg taken ÷ body weight in kg
Example: 50 kg patient, 25 mg/day × 100 days = 2500 mg ÷ 50 = 50 mg/kg cumulative

Repeat courses:

Allow at least 2-3 months between courses
~10% (Fitzpatrick) to ~33% (Rooks) require a second course
Predictors of relapse/need for repeat: age <16-17 years, male sex, short course, low cumulative dose, closed comedonal/microcystic acne
PCOS/hormonal acne: poor responders; exclude hyperandrogenemia in refractory/relapsing cases

Post-isotretinoin maintenance: Topical retinoid ± benzoyl peroxide reduces recurrence rate

(Fitzpatrick's block13, p.1438; Rooks 5e block28, pp.2669-2670)

5. Adverse Effects

A. Mucocutaneous (Dose-Dependent, Most Common)

Effect	Frequency/Notes
Cheilitis	Virtually all patients; hallmark of adequate dosing
Generalized xerosis	>50%
Dry mucous membranes (oral, nasal epistaxis, ocular)	>50%
Skin fragility, palmoplantar peeling	Common
Retinoid dermatitis/eczematous eruption	Especially cold, dry weather; can mimic allergy
Granulation tissue / pyogenic granuloma-like lesions	At acne cysts, periungual
Nail fragility, onycholysis, paronychia
Telogen effluvium, hair thinning
Photosensitivity
Staphylococcus aureus colonization/infection	Correlates with dryness

B. Ophthalmic

Xerophthalmia, blepharoconjunctivitis - common
Reduced night vision / night blindness
Keratitis, photophobia, corneal ulceration - rare
Corneal opacities, optic neuritis - reported

C. Musculoskeletal

Myalgias - most common musculoskeletal symptom (15%); check CPK in severe cases (rhabdomyolysis risk)
Arthralgias
Hyperostosis - more likely with high-dose/long-term use (keratinization disorders); less concern for standard 5-month acne courses
Bone density: single acne course does not significantly affect; repeated/chronic courses may cause osteopenia, fractures

D. Metabolic / Laboratory

Lab Abnormality	Frequency	Action
Hypertriglyceridemia	25-50%	>500: monitor frequently; >700-800 mg/dL: interrupt/add fibrate
Elevated cholesterol/LDL	20-30%	Diet, dose reduction
Transaminase elevation	<5-20% (mostly transient)	Usually mild; resolves
Leukopenia	~1.4%	Usually clinically insignificant
Thrombocytopenia	~0.9%	Usually clinically insignificant
Elevated ESR, platelet count	Less common

Risk of eruptive xanthomas and acute hemorrhagic pancreatitis at very high triglyceride levels

E. Neuropsychiatric

Pseudotumor cerebri (benign intracranial hypertension): headache, nausea, visual changes, papilledema - rare but serious
- Do not co-prescribe with tetracyclines (additive risk)
- Requires urgent neurological evaluation if suspected
Depression, suicidal ideation, psychosis: relationship controversial; meta-analysis of 9 studies found NO increased incidence of depression vs. untreated acne patients; biological plausibility exists (CNS penetration in animals; case reports); screen all patients and warn

F. Gastrointestinal

Nausea, anorexia, abdominal pain, diarrhea
IBD (inflammatory bowel disease): case reports and one study showing association with ulcerative colitis; causal relationship NOT established (Rooks 5e)

G. Teratogenicity (Category X - Most Serious Adverse Effect)

Not mutagenic - acts on organogenesis
Peak risk: ~3rd-4th week of gestation (neural crest cell toxicity)
No risk from male partner taking isotretinoin (not mutagenic; no abnormalities in sperm)

Retinoic acid embryopathy involves:

CNS: hydrocephalus, microcephaly, cortical agenesis, cerebellar hypoplasia, mental retardation
Cardiovascular: conotruncal + aortic arch defects (Tetralogy of Fallot, transposition of great vessels, truncus arteriosus, interrupted aortic arch)
Craniofacial: microtia, anotia, atresia of ear canal, microphthalmia, cleft palate, micrognathia
3rd and 4th pharyngeal pouches: thymic/parathyroid hypoplasia
Other: limb anomalies, anal/vaginal atresia

(Fitzpatrick's block13, p.1437-1438; Rooks 5e block28, pp.2675-2677)

6. Contraindications

Pregnancy (absolute) - Category X
Hypersensitivity to isotretinoin or parabens (vehicle)
Concurrent tetracyclines - pseudotumor cerebri risk
Severe hepatic insufficiency
Hypervitaminosis A
Uncontrolled hyperlipidemia

7. Key Drug Interactions

Drug	Interaction
Tetracyclines	Additive pseudotumor cerebri - avoid
Vitamin A supplements	Additive hypervitaminosis A toxicity
Warfarin	May affect anticoagulation
Alcohol	Worsens lipid effects
Corticosteroids	Used deliberately for acne fulminans

8. Laboratory Monitoring

Fitzpatrick's:

Baseline: CBC, LFTs, fasting lipid panel
Repeat at 4 and 8 weeks
If normal at 8 weeks + no risk factors: no further routine testing needed
CBC monitoring: not necessary in otherwise healthy patients

Rooks:

Baseline fasting lipids + LFTs
Monthly for first 2 months; then every 3 months if stable
Low-risk adolescents/young adults: baseline + 2 months; if normal, may reduce frequency
Triglycerides >800 mg/dL: discontinue therapy

IADVL/Indian (ERAISE ACNE 2025):

Laboratory monitoring especially in patients with metabolic risk factors
No consensus on universal frequency; risk-stratified approach recommended

9. Pregnancy Prevention Program

iPLEDGE (USA - mandatory):

Physicians and patients must register
Two negative pregnancy tests before starting
Two forms of effective contraception: start 1 month before, continue during, and for 1 month after
Monthly pregnancy tests during therapy
No more than 1 month's supply dispensed at a time
No blood donation during treatment or for 1 month after

Indian practice (IADVL/ERAISE):

No formal national registry comparable to iPLEDGE
Two forms of contraception recommended
Monthly pregnancy tests
Mandatory counseling with documented understanding

10. Special Situations

Acne Fulminans / Severe Initial Flare:

Start isotretinoin at very low dose (0.1 mg/kg/day)
Pre-treat with prednisone 0.5-1 mg/kg/day for 2-4 weeks before starting isotretinoin
Continue corticosteroids concurrently during initial weeks, taper slowly
Isotretinoin-induced acne fulminans: rare; more common in young adolescent males

Isotretinoin and Surgery/Procedures:

Traditional: avoid elective dermabrasion/surgery for 6-12 months after course
Systematic review (JAMA Dermatology 2017): individualize timing based on procedure type

Pediatric (<16-17 years):

Higher relapse rates; may need higher cumulative doses

Photosensitivity:

Advise sunscreen use throughout treatment

11. High-Yield Points for Exams (IADVL/Dermatology Board)

Only retinoid with significant sebum suppression - mechanism is sebocyte apoptosis, NOT RAR/RXR
Targets all 4 pathogenic factors of acne
Cumulative dose 120-150 mg/kg is the target to minimize relapse
Cheilitis in virtually all patients - marker of adequate dosing; reassure
NEVER combine with tetracyclines - pseudotumor cerebri
Contraception: 1 month before + during + 1 month after; only 1 month washout needed (clears in 2 weeks)
Not mutagenic - no teratogenic risk from male patients
Triglycerides >800 mg/dL: stop isotretinoin
Depression: meta-analyses show no increased risk vs. untreated acne; still screen all patients
IBD: not causally proven
Lidose/Absorica: food-independent absorption
Acne fulminans on isotretinoin: start low dose + steroid cover
PCOS/hormonal acne: poor response; investigate before repeat courses
Low-dose regimen (20 mg/day): acceptable for moderate acne in India; use adequate cumulative dose

References:

Fitzpatrick's Dermatology Vols 1-2, pp.1437-1438 (Acne Ch.), pp.3428-3445 (Retinoids Ch. 185)
Rooks/Dermatology 2-Volume Set 5e, pp.730-732 (Acne Ch.36), pp.2665-2678 (Retinoids Ch.126)
ERAISE ACNE: Indian expert consensus on isotretinoin, Dermatology & Therapy 2026
Kubba R et al. (IADVL/IAA). Acne in India: guidelines for management. IJDVL 2009;75:1-62

This is a shared conversation. Sign in to Orris to start your own chat.